Advertisement

Correspondence between negative symptoms and potential sources of secondary negative symptoms over time

  • Aida Farreny
  • Mark Savill
  • Stefan Priebe
Original Paper

Abstract

There has been a debate in the literature about the distinction between primary and secondary negative symptoms of schizophrenia. Our aim was to study the associations between negative symptoms and potential sources of secondary negative symptoms over time. A sample of 275 participants with at least mid-moderate negative symptoms was randomized into body psychotherapy or Pilates class in a previous study. No significant differences were found between groups over time and changes in the symptom domains were modest. The present investigation considers the longitudinal correlation between variables of interest at baseline, 3 and 9 months follow-up. Measures were the Clinical Assessment Interview for Negative Symptoms (CAINS), the Positive and Negative Symptom Scale (PANSS), the Calgary Depression Scale (CDSS) and the Simpson–Angus Extrapyramidal side-effects Scale (SAS). Mixed models were computed to test the longitudinal association between these variables. In a sensitivity analysis, the dosages of antipsychotic, illness duration and allocated intervention were taken into account. Overall, the course of extrapyramidal side-effects, depressive and positive symptoms was significantly related to the course of negative symptoms. Only extrapyramidal effects were longitudinally correlated to expressive negative symptoms. The sensitivity analyses showed unaltered results for positive symptoms and depression but a lack of association between extrapyramidal effects and the CAINS outcomes. In conclusion, the unambiguous interpretation between primary and secondary negative symptoms may lead to refined treatment approaches for schizophrenia and to increased effects of the interventions.

Keywords

Schizophrenia Primary negative symptoms Depression Positive symptoms Extrapyramidal effects CAINS 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Financial support

The data was collected as part of the NESS study, a trial funded by a grant from the National Institute for Health Research-Health Technology Assessment programme (REF: 08/116/68). The funding source had no role in the present study design, analysis, interpretation or manuscript submission.

References

  1. 1.
    Carbon M, Correll CU (2014) Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr 19:35–53. doi: 10.1017/S1092852914000601 CrossRefGoogle Scholar
  2. 2.
    Carpenter WT, Heinrichs DW, Alphs L (1985) Treatment of negative symptoms. Schizophr Bull 11:440–452CrossRefPubMedGoogle Scholar
  3. 3.
    Möller H-J (2007) Clinical evaluation of negative symptoms in schizophrenia. Eur Psychiatry 22:380–386. doi: 10.1016/j.eurpsy.2007.03.010 CrossRefPubMedGoogle Scholar
  4. 4.
    Carpenter WT Jr, Heinrichs WT, Wagman A (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145:578–583CrossRefPubMedGoogle Scholar
  5. 5.
    Kirschner M, Aleman A, Kaiser S (2016) Secondary negative symptoms—a review of mechanisms, assessment and treatment. Schizophr Res. doi: 10.1016/j.schres.2016.05.003 PubMedGoogle Scholar
  6. 6.
    Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32:214–219. doi: 10.1093/schbul/sbj053 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Savill M, Banks C, Khanom H, Priebe S (2015) Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data. Psychol Med 45:1613–1627. doi: 10.1017/S0033291714002712 CrossRefPubMedGoogle Scholar
  8. 8.
    Carpenter WT, Kirkpatrick B (2015) Correspondence: concepts and methods when considering negative symptom course. Psychol Med 45:2135–2136CrossRefPubMedGoogle Scholar
  9. 9.
    Czobor P, Volavka J (1996) Positive and negative symptoms: is their change related? Schizophr Bull 22:577–590CrossRefPubMedGoogle Scholar
  10. 10.
    Chen L, Johnston JA, Kinon BJ et al (2013) The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry 13:320. doi: 10.1186/1471-244X-13-320 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    an der Heiden W, Leber A, Häfner H (2016) Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 266:387–396. doi: 10.1007/s00406-016-0697-2 CrossRefPubMedGoogle Scholar
  12. 12.
    Strauss GP, Horan WP, Kirkpatrick B et al (2013) Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res 47:783–790. doi: 10.1016/j.jpsychires.2013.01.015 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Blanchard JJ, Cohen AS (2006) The structure of negative symptoms within Schizophrenia: implications for assessment. Schizophr Bull 32:238–245. doi: 10.1093/schbul/sbj013 CrossRefPubMedGoogle Scholar
  14. 14.
    Horan WP, Kring AM, Gur RE et al (2011) Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr Res 132:140–145. doi: 10.1016/j.schres.2011.06.030 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Barch DM (2013) The CAINS: theoretical and practical advances in the assessment of negative symptoms in schizophrenia. Am J Psychiatry 170:133–135. doi: 10.1176/appi.ajp.2012.12101329 CrossRefPubMedGoogle Scholar
  16. 16.
    Kirkpatrick B, Strauss GP, Nguyen L et al (2011) The brief negative symptom scale: psychometric properties. Schizophr Bull 37:300–305. doi: 10.1093/schbul/sbq059 CrossRefPubMedGoogle Scholar
  17. 17.
    Carpenter WT, Blanchard JJ, Kirkpatrick B (2016) New standards for negative symptom assessment. Schizophr Bull 42:1–3. doi: 10.1093/schbul/sbv160 CrossRefPubMedGoogle Scholar
  18. 18.
    Kelley ME, van Kammen DP, Allen DN (1999) Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiatry 156:406–411. doi: 10.1176/ajp.156.3.406 PubMedGoogle Scholar
  19. 19.
    Priebe S, Savill M, Wykes T et al (2016) Effectiveness of group body psychotherapy for negative symptoms of schizophrenia: multicentre randomised controlled trial. Br J Psychiatry 209:54–61. doi: 10.1192/bjp.bp.115.171397 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    World Health Organization (WHO) (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, GenevaGoogle Scholar
  21. 21.
    Kring AM, Gur RE, Blanchard JJ et al (2013) The clinical assessment interview for negative symptoms (CAINS): final development and validation. Am J Psychiatry 170:165–172. doi: 10.1176/appi.ajp.2012.12010109 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276CrossRefPubMedGoogle Scholar
  23. 23.
    Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538–546CrossRefPubMedGoogle Scholar
  24. 24.
    Addington D, Addington J, Maticka-Tyndale E (1993) Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 22:39–44CrossRefGoogle Scholar
  25. 25.
    Lako IM, Bruggeman R, Knegtering H et al (2012) A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J Affect Disord 140:38–47. doi: 10.1016/j.jad.2011.10.014 CrossRefPubMedGoogle Scholar
  26. 26.
    Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19CrossRefPubMedGoogle Scholar
  27. 27.
    WHO Collaborating Centre for Drug Statistics Methodology (2013) Guidelines for ATC classification and DDD assignment. Norwegian Institute of Public Health, Oslo. doi: 10.1021/la902623c Google Scholar
  28. 28.
    Nosè M, Tansella M, Thornicroft G et al (2008) Is the defined daily dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol 23:287–290. doi: 10.1097/YIC.0b013e328303ac75 CrossRefPubMedGoogle Scholar
  29. 29.
    Sweileh WM, Odeh JB, Shraim NY et al (2014) Evaluation of defined daily dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization. Saudi Pharm J 22:127–132. doi: 10.1016/j.jsps.2013.03.003 CrossRefPubMedGoogle Scholar
  30. 30.
    IBM SPSS statistics for windows 22.0 (2013) IBM Corp, Armonk, New YorkGoogle Scholar
  31. 31.
    Gozdzik-Zelazny A, Borecki L, Pokorski M (2011) Depressive symptoms in schizophrenic patients. Eur J Med Res 16:549–552CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Klaassen RMC, Heins M, Luteijn LB et al (2013) Depressive symptoms are associated with (sub)clinical psychotic symptoms in patients with non-affective psychotic disorder, siblings and healthy controls. Psychol Med 43:747–756. doi: 10.1017/S0033291712001572 CrossRefPubMedGoogle Scholar
  33. 33.
    Marder SR, Kirkpatrick B (2014) Defining and measuring negative symptoms of schizophrenia in clinical trials. Eur Neuropsychopharmacol 24:737–743. doi: 10.1016/j.euroneuro.2013.10.016 CrossRefPubMedGoogle Scholar
  34. 34.
    Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF (2000) Differentiating primary from secondary negative symptoms in Schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry 157:1461–1466. doi: 10.1176/appi.ajp.157.9.1461 CrossRefPubMedGoogle Scholar
  35. 35.
    Tandon R, DeQuardo JR, Taylor SF et al (2000) Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 45:191–201CrossRefPubMedGoogle Scholar
  36. 36.
    Artaloytia JF, Arango C, Lahti A et al (2006) Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 163:488–493. doi: 10.1176/appi.ajp.163.3.488 CrossRefPubMedGoogle Scholar
  37. 37.
    Strauss JS, Carpenter WT, Bartko JJ (1974) The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 11:61–69CrossRefGoogle Scholar
  38. 38.
    Foussias G, Agid O, Fervaha G, Remington G (2014) Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol 24:693–709. doi: 10.1016/j.euroneuro.2013.10.017 CrossRefPubMedGoogle Scholar
  39. 39.
    Wallwork RS, Fortgang R, Hashimoto R et al (2012) Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res 137:246–250. doi: 10.1016/j.schres.2012.01.031 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Fusar-Poli P, Papanastasiou E, Stahl D et al (2015) Treatments of negative symptoms in Schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 41:892–899. doi: 10.1093/schbul/sbu170 CrossRefPubMedGoogle Scholar
  41. 41.
    Lutgens D, Gariepy G, Malla A (2017) Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis. Br J Psychiatry 210:324–332. doi: 10.1192/bjp.bp.116.197103 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Unit for Social and Community Psychiatry, WHO Collaborating Centre for Mental Health Services DevelopmentQueen Mary University of LondonLondonUK
  2. 2.Department of Psychiatry, School of MedicineUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations